Philip Morris Shares Surge on FDA Nicotine Pouch Fast-Track Trading Volume Spikes 49.6% to 980M Ranked 101st in Market Activity

. 8, . The move followed the U.S. Food and Drug Administration’s (FDA) reported plan to launch a fast-track review program for nicotine pouches, . This initiative, initially spanning several years, now targets expedited evaluations for products from Philip Morris, Altria, and other tobacco firms, addressing prolonged regulatory uncertainties.

The FDA’s accelerated timeline could streamline market access for Philip Morris’s Zyn nicotine pouches, which have historically faced lengthy authorization delays. . This shift aligns with Philip Morris’s strategic pivot toward smoke-free alternatives, including a potential divestiture of its U.S. cigar business acquired via the Swedish Match AB takeover. The move underscores the sector’s focus on lower-risk products amid evolving consumer and regulatory landscapes.

Industry stakeholders have lobbied for streamlined FDA processes, citing White House pressure to enhance efficiency. Philip Morris’s stock performance reflects market anticipation of these regulatory changes, . Meanwhile, the FDA’s pilot program excludes youth usage concerns surrounding nicotine pouches, a critical factor as the U.S. remains the largest market for smoke-free alternatives. .

To run this back‐test accurately I need a bit more detail about the universe and trade mechanics: 1. Universe • Which market or exchange should the 500 stocks come from? 2. Trade execution assumptions • Enter at the close of the ranking day and exit at the close of the next day? 3. Portfolio construction • Equal-weight across the 500 names? If you’re happy with the defaults just let me know and I’ll proceed.